We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Tools
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| International Biotechnology Trust Plc | LSE:IBT | London | Ordinary Share | GB0004559349 | ORD 25P |
| Price Change | % Change | Share Price | Shares Traded | Last Trade
|
|
|---|---|---|---|---|---|
| 11.00 | 1.85% | 607.00 | 29,133 | 16:35:19 |
| Bid Price | Offer Price | High Price | Low Price | Open Price | |
|---|---|---|---|---|---|
| 604.00 | 610.00 | 606.00 | 602.00 | 602.00 | |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Trust,ex Ed,religious,charty | 12.06M | 6.81M | 0.1739 | 34.62 | 235.78M |
| Last Trade Time | Trade Type | Trade Size | Trade Price | Currency |
|---|---|---|---|---|
| 16:45:00 | O | 54 | 598.00 | GBX |
| Date | Time | Source | Headline |
|---|---|---|---|
| 06/12/2023 | 10:25 | UKREG | Intl. Biotechnology Trust PLC Net Asset Value(s) |
| 05/12/2023 | 18:29 | UKREG | Intl. Biotechnology Trust PLC Transaction in Own Shares |
| 05/12/2023 | 10:37 | UKREG | Intl. Biotechnology Trust PLC Net Asset Value(s) |
| 04/12/2023 | 17:17 | UKREG | Intl. Biotechnology Trust PLC Transaction in Own Shares |
| 04/12/2023 | 10:54 | UKREG | Intl. Biotechnology Trust PLC Net Asset Value(s) |
| 01/12/2023 | 11:10 | UKREG | Intl. Biotechnology Trust PLC Net Asset Value(s) |
| 01/12/2023 | 07:00 | UKREG | Intl. Biotechnology Trust PLC Total Voting Rights |
| 30/11/2023 | 10:36 | UKREG | Intl. Biotechnology Trust PLC Net Asset Value(s) |
| 29/11/2023 | 17:14 | UKREG | Intl. Biotechnology Trust PLC Transaction in Own Shares |
| 29/11/2023 | 10:09 | UKREG | Intl. Biotechnology Trust PLC Net Asset Value(s) |
International Biotechnol... (IBT) Share Charts1 Year International Biotechnol... Chart |
|
1 Month International Biotechnol... Chart |
Intraday International Biotechnol... Chart |
| Date | Time | Title | Posts |
|---|---|---|---|
| 14/11/2023 | 08:21 | International Biotechnolgy Trust | 384 |
| 29/4/2019 | 09:54 | International Boitechnology Trust | 148 |
| 21/10/2001 | 03:31 | "Biotech names selling on air" | 2 |
| 28/12/2000 | 12:08 | Soros buys Int.Biotech stake | 5 |
| 17/7/2000 | 17:11 | Int Biotech | 1 |
| Trade Time | Trade Price | Trade Size | Trade Value | Trade Type |
|---|---|---|---|---|
| 2023-12-06 16:45:18 | 598.00 | 54 | 322.92 | O |
| 2023-12-06 16:22:01 | 606.00 | 500 | 3,029.98 | O |
| 2023-12-06 16:08:11 | 606.00 | 150 | 909.00 | O |
| 2023-12-06 16:07:30 | 602.00 | 500 | 3,010.00 | AT |
| 2023-12-06 15:52:00 | 603.04 | 717 | 4,323.83 | O |
| Top Posts |
|---|
Posted at 06/12/2023 08:20 by International Biotechnol... Daily Update International Biotechnology Trust Plc is listed in the Trust,ex Ed,religious,charty sector of the London Stock Exchange with ticker IBT. The last closing price for International Biotechnol... was 596p.International Biotechnol... currently has 39,166,607 shares in issue. The market capitalisation of International Biotechnol... is £235,782,974. International Biotechnol... has a price to earnings ratio (PE ratio) of 34.62. This morning IBT shares opened at 602p |
Posted at 07/11/2023 15:14 by speedsgh Annual Financial Report - from CHAIR'S STATEMENT... OUTLOOK It has been a volatile year for all investors as markets have swung from facing the reality of global inflation and the threat of recession to the belief that the interest rate cycle may be nearing a peak and the worst may be over. At the time of writing, the devastating news of a resurgence of the conflict in the Middle East has shaken market confidence. The continuing war in Ukraine and the increasingly tense relations between the US and China have further exacerbated the uncertainty within the investment environment. Nevertheless, the Board shares the Investment Managers' views that there are grounds for optimism. Whilst higher costs of capital have had a substantial effect on the funding environment for early stage drug discovery companies, the fundamentals of the sector remain very much intact: namely a growing elderly population, a rising middle class, and an increasing demand for treatments to cure disease and enhance the quality of our lives. This spend is, to a large degree, non-discretionary. Furthermore, scientific innovation in areas such as personalised targeted therapies and the application of artificial intelligence has led to faster, positive outcomes from clinical trials and better prospects for patients. I would like to take this opportunity to thank my fellow Directors, the investment management team, and our professional advisers, all of whom have worked hard this year to ensure that we achieved the optimum outcome for our shareholders. We are excited about the opportunities for IBT within the Schroders stable and are looking forward to the future with confidence. -------------------- from FUND MANAGER'S REVIEW... OUTLOOK After experiencing remarkable highs in 2020 and 2021, the biotech industry faced significant challenges in recent years. However, there are compelling reasons for optimism as we move forward. The NBI has demonstrated resilience by rebounding 20% from mid-2022 lows in dollar terms. Smaller biotech companies, though affected by rising interest rates, continue to present appealing valuations, offering unique investment opportunities. The confluence of rising interest rates and macroeconomic conditions, along with evolving industry dynamics related to the FTC and the Inflation Reduction Act, has created headwinds for the biotech sector. However, it is noteworthy that these challenges have had minimal impact on the valuations of innovative small and mid-cap biotech companies which represented 51% of the Company's NAV at the end of August 2023. The recent period of valuation adjustments has stimulated increased M&A activity within the industry. We anticipate this trend to persist. Biotechnology continues to display robust innovation, boasting strong numbers of drug approvals and increasing numbers of clinical trials. Notably, emerging modalities such as gene and cell therapies hold transformative potential for addressing significant unmet medical needs across various diseases. In conclusion, the biotech industry stands resilient and forward-looking. Increasing demand for high quality therapies, M&A activities, productivity improvements through consolidation, sustained innovation, and the allure of undervalued companies in this dynamic landscape contribute to a promising outlook for biotech investments. As we navigate these opportunities, our commitment to delivering value to our investors remains steadfast. We look forward to a future marked by growth and transformation in the biotech sector. |
Posted at 03/8/2023 12:02 by speedsgh Appointment of New Fund Manager - · Schroders selected as IBT's Fund Manager and Alternative Investment Fund Manager · Continuity of investment approach and dividend policy · Ailsa Craig and Marek Poszepczynski to continue as the Company's portfolio managers The Board of IBT is pleased to announce that it has decided to appoint Schroder Unit Trusts Ltd ("Schroders") as the Company's Fund Manager and Alternative Investment Fund Manager ("AIFM") with a mandate to continue IBT's investment policy, which offers access to the fast-growing biotechnology sector through an actively managed, diversified strategy. This appointment is consistent with the feedback received from shareholders, which endorsed the continuity of the Company's investment approach under the existing investment management team and retaining the dividend policy. As such, the Board believes that Schroders' appointment will deliver positive long-term benefits for IBT and its shareholders. Ailsa Craig and Marek Poszepczynski have accepted Schroders' conditional offer for them to continue as the Company's portfolio managers. Ailsa and Marek took on the position of IBT's Joint Lead Managers in March 2021, having been involved in managing IBT since 2006 and 2013 respectively. The Company's net asset value ("NAV") has outperformed its benchmark, the Nasdaq Biotechnology Index, by 6.7% since March 2021 and by 9.0% and 35.5% respectively over the last five and ten years(1). Schroders will provide a platform from which IBT can continue to deliver its differentiated proposition of solid relative returns with lower volatility, and an annual dividend of 4% of NAV(2). There are also no plans to change the Company's discount and premium management policy. These appointments are subject to finalisation of legal documentation and to regulatory approval, and IBT is expected to transition formally to Schroders in November 2023, following publication of the Company's annual results to 31 August 2023. IBT will continue to have a relationship with SV Health Managers LLP ("SV Health Investors") in connection with the existing unquoted portfolio, which is principally invested in two SV Health Investors funds. The Company has consulted with a number of its major shareholders who have indicated their support for the Board's process. In accordance with the Company's articles of association, which provide for a continuation vote every two years, a continuation resolution will be proposed at the Company's December 2023 Annual General Meeting. |
Posted at 25/4/2023 13:24 by davidosh IBT are on the show this afternoon and it is free to join and also receive the recording |
Posted at 13/3/2023 12:58 by speedsgh As per c34's post above...Portfolio Update as at 13 March 2023 - The Company notes that Pfizer Inc (NYSE: PFE) has announced that it entered a definitive agreement to acquire IBT's portfolio company Seagen Inc. (Nasdaq: SGEN) for $229 per share which represents a 32.7% premium to the closing price of Seagen Inc on 10 March 2023 of $172.61. Prior to the announcement on 13 March 2023, IBT owned 200,200 shares in Seagen, which is the trust's largest position representing 10.2% of IBT's Net Asset Value, as at the close on Friday 10 March 2023. |
Posted at 16/12/2022 10:25 by speedsgh International Biotech shares rally on strong dealflow - Shares in International Biotechnology Trust (IBT) have rallied more than 3% after a flurry of good news this week, including Amgen’s acquisition of its largest position Horizon Therapeutics. The US pharma giant agreed to acquire the biotech stock, which focuses on developing drugs for rare autoimmune diseases, for $116.5 per share on Monday, a nearly 50% premium to the share price when talks began last month. Given its 13.5% weighting in International Biotechnology’ The £283m trust also announced a material revaluation to one of its unquoted investments managed by parent company SV Health Managers, which will lead to a £2.5m, or 0.8%, uplift to NAV. It is unclear which company it refers to, but on Tuesday SV Health Managers issued a press release stating that Japanese pharma company Takeda had agreed to acquire Nimbus Therapeutics’ allosteric TYK2 inhibitor, which addresses multiple immune-mediated diseases. Nimbus will receive $4bn upfront cash and up to $2bn in commercial milestone payments, it said. Following the investment company’s annual results in November, manager Ailsa Craig told Citywire that the US Inflation Reduction Act, which was passed in August this year, will likely increase the levels of mergers and acquisitions. ‘The positive for our sector and our companies is: will that increase the demand for M&A? I think maybe it could. It looks like the biotech market sector shrugged it off but it’s probably all these market forces balancing each other out,’ she said. Since close on Friday, IBT’s shares have rallied 3.3% to 713p. Over five years, shareholders have enjoyed a 42.2% total return, ahead of the 25.9% average in the Biotechnology & Healthcare peer group tracked by the Association of Investment Companies. |
Posted at 14/12/2022 07:30 by speedsgh Portfolio Update as at 13 December 2022 - The Company notes that there has been a material adjustment to the valuation of an investment from the unquoted portfolio managed by SV Health Managers LLP in which the Company is invested. The net asset value of the Company will therefore increase by £2.5m ($3.1m) which corresponds to 6p per share uplift and will be incorporated into today's unaudited net asset value (calculated on the AIC basis). |
Posted at 07/12/2022 16:13 by speedsgh Dividend Declaration - So 28.00p dividend for the current FY... interim (Jan 23) - 14.00p -------------------- TOTAL FY 2021/22 - 31.40p final (Aug 22) - 15.70p interim (Jan 22) - 15.70p -------------------- TOTAL FY 2020/21 - 28.40p final (Aug 21) - 14.20p interim (Jan 21) - 14.20p -------------------- TOTAL FY 2019/20 - 24.80p final (Aug 20) - 12.40p interim (Jan 20) - 12.40p -------------------- TOTAL FY 2018/19 - 28.00p final (Aug 19) - 14.00p interim (Jan 19) - 14.00p -------------------- TOTAL FY 2017/18 - 27.00p final (Aug 18) - 13.50p interim (Jan 18) - 13.50p -------------------- TOTAL FY 2016/17 - 23.00p final (Aug 17) - 11.50p interim (Jan 17) - 11.50p |
Posted at 27/7/2022 09:39 by speedsgh Dividend Declaration - At the Annual General Meeting held on 8 December 2021, Shareholders approved the Company's dividend policy of making dividend payments, equivalent to 4 per cent. of the Company's Net Asset Value as at the last day of the preceding financial year (31 August), through two equal semi-annual distributions. In accordance with this policy, the first Interim Dividend for the period ending 31 August 2022 was paid in January 2022. The Directors have today declared the second Interim Dividend for the period ending 31 August 2022 of 15.7p per Ordinary Share. The second Interim Dividend will be payable on Friday, 26 August 2022 to holders of Ordinary Shares on the Register at the close of business on Friday, 5 August 2022 (ex-dividend Shares on the Register at Thursday, 4 August 2022). |
Posted at 10/5/2022 18:23 by speedsgh $IBT 4.1% of the latest NAV for #IntlBiotechTrust is in Biohaven $BHVN which has just agreed an $11.6bn cash bid from Pfizer $PFE. This adds ca.$3.0m/£2.4m to valuation. Uplift on last night's NAV is ca.3%. -------------------- From IBT website... Top 10 Quoted Investments (as at 28/2/22) - 5.1% of NAV - Horizon Therapeutics 5.0% of NAV - Neurocrine Biosciences 5.0% of NAV - Incyte 4.5% of NAV - Ultragenyx 4.5% of NAV - Illumina 4.3% of NAV - Amgen 4.1% of NAV - Biohaven Pharmaceuticals 4.1% of NAV - Mirati Therapeutics 4.1% of NAV - PTC Therapeutics 3.0% of NAV - Argenx |
Posted at 04/5/2022 07:11 by speedsgh Half Year Report - SUMMARY In the first six months of the year the Fund Manager produced strong relative performance, albeit against a weak biotechnology market. For the six months ended 28 February 2022, the NAV per share returned -13.1%. By comparison, the NBI returned -23.0%. Over the same period, the ordinary share price of the Company returned -9.4%. Although negative returns are always disappointing, it is encouraging that IBT has substantially outperformed its comparator index over this difficult period for biotechnology shares. The Company's share price continues to outperform the NBI by 1.7% and 8.7% respectively over a 3 and 5-year period, with the 1-year period underperforming by -0.6%. All figures are on a sterling adjusted total return basis, with dividends reinvested... OUTLOOK The Fund Manager and Directors will continue to actively monitor the global economic and geopolitical situation and any potential impact on the biotechnology sector's prospects, financial condition and outlook. Although the market has been shaken by the horrors of the war in Eastern Europe and its concomitant economic impact, the fundamentals of the biotech industry remain intact. The companies that the Company is invested in remain strong with innovation still continuing apace and demand for new therapies rising, as the elderly population grows and developing markets gain better access to medicines. The Company has not invested in any Russian companies. From a broader economic perspective, the lessening impact of the pandemic should be positive for economic growth but brings with it the risk of inflation. The past months have seen volatility in the market which is likely to continue but the Directors are encouraged that valuations in the biotech sector are currently at historically low levels and share the Fund Manager's optimism for a rebound. Catalysts could include a return of M&A to the sector fuelled by a combination of cash rich big pharmaceutical companies looking to replenish their pipelines and smaller biotech companies trading at attractive valuations. The Fund Manager's active investment strategy will ensure that the Company is well placed to identify possible beneficiaries of a rebound. As a Board we have confidence that the Fund Manager will continue to seek to deliver market beating returns. |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
|
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions Support: +44 (0) 203 8794 460 | support@advfn.com |
| ADVFN UK Investors Hub ADVFN Italy ADVFN Australia ADVFN Brazil |
| ADVFN Canada ADVFN Germany ADVFN Japan ADVFN Mexico |
| ADVFN France ADVFN US ADVFN Korea |
